HeartSciences Introduces the MyoVista® Wavelet ECG at the 2018 Congress of the European Society of Cardiology (ESC)
Tuesday, August 21, 2018
HeartSciences , a medical device company that is developing next-generation ECG devices using continuous wavelet transform (CWT) -based signal processing. artificial intelligence, is proud to announce its participation as an exhibitor at the next 2018 congress of the European Society of Cardiology (ESC). The congress will be held at Messe Munich International in Munich, Germany from August 25 to 29, 2018. HeartSciences will present its cardiac test device with MyoVista® wavelet ECG as well as the results of a recent clinical study, published in the Journal of the American College of Cardiology ( JACC )
The JACC article titled " Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG " presents the results of the clinical study initiated by investigators. , on the evaluation of the feasibility of the MyoVista ® wavelet ECG as a diagnostic tool for predicting myocardial relaxation abnormalities. The results of the study demonstrate that the patented MyoVista technology based on continuous wavelet transform (CWT) -based signal processing can detect myocardial relaxation disorders related to DDVG.
About HeartSciences
HeartSciences advances the field of electrocardiography by applying wavelet signal processing and artificial intelligence to develop next-generation ECG technology. Wavelet signal processing is currently used in many sectors as it is an important tool that provides valuable information and new data for spectral signal analysis. MyoVista wav ECG cardiac test device of HeartSciences is a 12-electrode standby electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. This patented technology focuses on energy-related information rather than conventional voltage-based information. HeartSciences' mission is to provide accurate and affordable screening for the early detection of heart disease.
In addition to patented computing, the MyoVista wav ECG device also offers the capabilities of a complete 12-electrode resting ECG, including analysis using the Glasgow algorithm, one of the most respected interpretation algorithms in the world. world. The device has a 15.6-inch high resolution touch screen, and incorporates many of the features commonly found in tablets. It requires only minimal user training, because its user manual is easy and intuitive. The MyoVista wav ECG device is not currently approved for sale or distribution in the United States and is not currently authorized by the FDA.
HeartSciences is an American private company based in Southlake, Texas.
For more information, visit www.heartsciences.com .
The text of the communiqué resulting from a translation must in no way be considered official. The only version of the release that is authentic is that of the release in its original language. The translation will always have to be confronted with the source text, which will make jurisprudence.
contacts
HeartSciences
Gene Gephart, + 1-737-346-1089
gene.gephart@heartsciences.com
or
Contact Investors
Zimmons International Communications
Jennifer K. Zimmons, + 1-917-214-3514
jzimmons@zimmonsic.com